TICKERNERD
Menu
DMACDMACHealthcare · Biotechnology

DMAC Stock Forecast: DiaMedica Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$9.25
−2.84% on the day

The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. hold a median 12-month price target of $13 — +40.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 56 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$513.4M
Ticker Nerd rank
56/ 100
Median analyst target
$13
Analysts covering
5
Revenue$0.0
Operating income−$10.5M
Net income−$10.1M
Free cash flow−$8.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+6.1%
1M
+11.9%
YTD
+16.2%
1Y
+32.1%
From 52W high
−5.8%
From 52W low
+73.5%
$5.33
$9.82
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DMAC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DiaMedica Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
56/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
77
Volatility
76
Value
72
Accruals
65
Revisions
56
Size
52
Issuance
42
Growth
38
Quality
20

Momentum (77): The shares have been drifting up relative to others.

Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DMAC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DMAC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5.00$10.00$15.00$20.00$25.00Jan 26Apr 26Jul 26Oct 26DMACHigh $25Median $13Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $11Median $13High $25

The green dot is the last close — the median target sits +40.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026HC Wainwright & Co.ReiteratesBuy$12
14 Nov 2025Cantor FitzgeraldInitiatesOverweight—
14 Nov 2025Cantor FitzgeraldInitiatesOverweight$25
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
18 July 2025Craig-HallumMaintainsBuy—
18 July 2025HC Wainwright & Co.MaintainsBuy—
18 July 2025Lake StreetMaintainsBuy—
29 May 2025HC Wainwright & Co.ReiteratesBuy—
19 Mar 2025HC Wainwright & Co.MaintainsBuy—
15 Nov 2024HC Wainwright & Co.ReiteratesBuy—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—
7 Oct 2024HC Wainwright & Co.InitiatesBuy—
16 Aug 2024OppenheimerReiteratesOutperform—
24 Apr 2024Craig-HallumAssumesBuy$8.00
21 Mar 2024Craig-HallumMaintainsBuy—
21 Mar 2024OppenheimerReiteratesOutperform—
22 June 2023OppenheimerUpgradeOutperform—
7 July 2022Craig-HallumMaintainsBuy—
7 July 2022Lake StreetMaintainsBuy—
7 July 2022OppenheimerDowngradePerform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DMAC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DMAC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, DiaMedica Therapeutics, Inc. returned +32.1% against +12.4% for the S&P 500, dividends included.

DMAC vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140Jan 26Apr 26Jul 26Oct 26DMACS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DMAC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

DiaMedica Therapeutics, Inc. (DMAC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.4×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
13.3×

Cheaper than 7% of US stocks

EV / EBITDA
−12.0×

Cheaper than 87% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−114.6%

Higher than 12% of US stocks

Return on assets
−64.1%

Higher than 6% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DiaMedica Therapeutics, Inc. (DMAC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DiaMedica Therapeutics, Inc. has a market value of $513.4M and an enterprise value of $470.1M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$37.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$31.5M.

  • Shares outstanding: 53.9M.

  • Trailing P/E: −13.4×; forward P/E: −12.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • DiaMedica Therapeutics, Inc. employs 35 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 30 Oct 2026

Data provided by Twelve Data

Peers

DMAC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
DMACDiaMedica Therapeutics, Inc.$513.4M56
CBIOCrescent Biopharma, Inc.$498.2M46
ARVNArvinas, Inc.$504.8M69
CTMXCytomX Therapeutics, Inc.$505.9M42
GYREGyre Therapeutics, Inc.$507.8M48
ETRAElectra Therapeutics, Inc.$508.4M1
OCSOculis Holding AG$509.9M27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DiaMedica Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DMAC news & analysis

DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial

Business Wire · 22 Oct 2026positive

DiaMedica Therapeutics announced that the 200th patient has enrolled in its Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke. Enrollment reached the prespecified threshold for the trial’s planned interim analysis.

Why it matters — The milestone marks progress toward the planned interim analysis of the company’s pivotal acute ischemic stroke trial.

DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar

Business Wire · 19 Oct 2026neutral

DiaMedica Therapeutics rescheduled its virtual fetal growth restriction key opinion leader webinar from October 23 to November 24, 2026, at 8:00 a.m. Eastern Time. The company said the new date will allow it to expand the presentation to include preliminary information.

Why it matters — The schedule change and expanded presentation may be relevant to DMAC watchers following the company’s fetal growth restriction program.

DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results

Business Wire · 30 Sept 2026positive

DiaMedica Therapeutics announced it will host a virtual key opinion leader webinar on October 23, 2026 to discuss fetal growth restriction and the therapeutic rationale for evaluating DM199 (rinvecalinase alfa) as a potential treatment, featuring early Phase 2 FGR results.

Why it matters — The webinar highlights the company's progress in advancing DM199 within its fetal growth restriction program and provides a platform for sharing early Phase 2 clinical data.

DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences

Business Wire · 2 Sept 2026neutral

DiaMedica Therapeutics announced that company management will participate in four upcoming investment bank conferences in New York in September 2026, including the Citi Biopharma Back to School Summit and the Cantor Global Healthcare Conference. CEO Rick Pauls is scheduled for a fireside chat as part of the events.

Why it matters — A DiaMedica watcher would care because the conference appearances give management an opportunity to present the company's pipeline to investors and analysts.

Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet

Zacks Investment Research · 26 Aug 2026positive

Zacks Research reports that the average Wall Street price target for DiaMedica Therapeutics implies a potential upside of about 130%. The item notes that while the reliability of this metric is questionable, positive earnings estimate revisions could support upside in the stock.

Why it matters — DMAC watchers would care because analyst price targets and earnings estimate trends offer signals about how the market currently views the stock's potential.

FAQ

Frequently asked questions about DMAC stock

What is the DMAC stock price forecast for 2026-2027?

The 5 Wall Street analysts covering DiaMedica Therapeutics, Inc. have a median 12-month price target of $13, with estimates ranging from $11 to $25. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DMAC stock a buy right now?

Of the 5 analysts covering DiaMedica Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DiaMedica Therapeutics, Inc. 56 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DMAC?

As at 31 Oct 2026, DiaMedica Therapeutics, Inc. ranks 56 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (77 of 100).

Will DMAC stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +40.5% from the last close, and Ticker Nerd's factor model ranks DiaMedica Therapeutics, Inc. 56 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DMAC stock forecast for 2030?

No analyst covering DiaMedica Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DMAC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $25 over the next 12 months.

How has DMAC stock performed over the past year?

DiaMedica Therapeutics, Inc. returned +32.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DiaMedica Therapeutics, Inc. do?

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases.

What is the latest news on DMAC?

The most recent item we track (Business Wire, 22 Oct 2026): "DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial". DiaMedica Therapeutics announced that the 200th patient has enrolled in its Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke. Enrollment reached the prespecified threshold for the trial’s planned interim analysis.

Company

About DiaMedica Therapeutics, Inc.

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious vascular and ischemic diseases. Its current pipeline is centered on DM199, a recombinant form of human tissue kallikrein-1 being studied for acute ischemic stroke, preeclampsia, fetal growth restriction, and other conditions linked to impaired blood flow. The company also advances DM300, a recombinant human ulinastatin candidate in preclinical development for inflammatory disorders. DiaMedica Therapeutics serves the neuroscience, women’s health, renal, and inflammatory disease areas through therapies designed to address significant unmet medical needs. Headquartered in Minneapolis, Minnesota, DiaMedica Therapeutics Inc. operates as a specialized biotech platform focused on recombinant protein-based drug development.

CEO Mr. Dietrich John Pauls MBA · 35 employees · United States · https://www.diamedica.com